V1221 INTRAOPERATIVE USE OF A PROSTATE SPECIFIC MEMBRANE ANTIGEN-BASED FLUORESCENT IMAGING AGENT FOR PROSTATE CANCER IN A MOUSE MODEL

Abstract

You have accessJournal of UrologyProstate Oncology1 Apr 2011V1221 INTRAOPERATIVE USE OF A PROSTATE SPECIFIC MEMBRANE ANTIGEN-BASED FLUORESCENT IMAGING AGENT FOR PROSTATE CANCER IN A MOUSE MODEL John Eifler, Wasim Chowdhury, Mark Castanares, Catherine Foss, Netto George, Martin Pomper, and Ronald Rodriguez John EiflerJohn Eifler Baltimore, MD More articles by this author , Wasim ChowdhuryWasim Chowdhury Baltimore, MD More articles by this author , Mark CastanaresMark Castanares Baltimore, MD More articles by this author , Catherine FossCatherine Foss Baltimore, MD More articles by this author , Netto GeorgeNetto George Baltimore, MD More articles by this author , Martin PomperMartin Pomper Baltimore, MD More articles by this author , and Ronald RodriguezRonald Rodriguez Baltimore, MD More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2011.02.879AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES The identification and elimination of positive surgical margins remains a goal of prostate cancer surgery. Recently a low-molecular weight agent that targets the prostate specific membrane antigen (PSMA) and emits light in the near infrared (NIR) range, YC-27, was developed at our institution. METHODS In the first experiment, 6 × 105 PSMA-expressing human prostate cancer cells (LNCaP) were incubated with 10 nM YC-27 for thirty minutes. This suspension was washed three times, and injected subcutaneously in the flank of a nude mouse. An additional 6 × 105 LNCaP cells that were not incubated with YC-27 were injected in the opposite side. A NIR based imager (Fluobeam; Fluoptics, Grenoble, France) was used in addition to visible light to detect LNCaP cells intraoperatively in real-time. In a second experiment, human prostate cancer cells (PC3-PIP) was injected orthotopically into a nude mouse. Sixteen days later, YC-27 was injected intravenously. After 24 hours, the mouse was sacrificed and explored using the Fluobeam. RESULTS Peak emission of YC-27 occurred near 800 nm and was visible through the skin. PSMA-positive prostate cancer cells (LNCaP) were visible when incubated with the agent, while LNCaP cells not incubated with YC-27 were not detected. NIR fluorescence imaging allowed real-time detection and removal of a human prostate cancer cell suspension that was invisible in white light. Furthermore, a 2mm human prostate tumor (PC3-PIP) was detected with fluorescence imaging and histologically proven to be prostate cancer. CONCLUSIONS A PSMA-binding small molecule that emits in the NIR range allows real-time, intraoperative identification of small tumor burdens. This agent may be useful for laparoscopic, robotic, or open prostate surgery and warrants further study. © 2011 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 185Issue 4SApril 2011Page: e490 Advertisement Copyright & Permissions© 2011 by American Urological Association Education and Research, Inc.MetricsAuthor Information John Eifler Baltimore, MD More articles by this author Wasim Chowdhury Baltimore, MD More articles by this author Mark Castanares Baltimore, MD More articles by this author Catherine Foss Baltimore, MD More articles by this author Netto George Baltimore, MD More articles by this author Martin Pomper Baltimore, MD More articles by this author Ronald Rodriguez Baltimore, MD More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...